PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Abstract In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown.
PMID
Related Publications

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors

Mayor MeshTerms
Keywords
Journal Title the new england journal of medicine
Publication Year Start




PMID- 28854085
OWN - NLM
STAT- In-Process
DA  - 20170830
LR  - 20170905
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 9
DP  - 2017 Aug 31
TI  - Liraglutide and Renal Outcomes in Type 2 Diabetes.
PG  - 839-848
LID - 10.1056/NEJMoa1616011 [doi]
AB  - BACKGROUND: In a randomized, controlled trial that compared liraglutide, a
      glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes
      and high cardiovascular risk who were receiving usual care, we found that
      liraglutide resulted in lower risks of the primary end point (nonfatal myocardial
      infarction, nonfatal stroke, or death from cardiovascular causes) and death.
      However, the long-term effects of liraglutide on renal outcomes in patients with 
      type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal 
      outcomes of that randomized, controlled trial in which patients were assigned to 
      receive liraglutide or placebo. The secondary renal outcome was a composite of
      new-onset persistent macroalbuminuria, persistent doubling of the serum
      creatinine level, end-stage renal disease, or death due to renal disease. The
      risk of renal outcomes was determined with the use of time-to-event analyses with
      an intention-to-treat approach. Changes in the estimated glomerular filtration
      rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients
      underwent randomization, and the median follow-up of the patients was 3.84 years.
      The renal outcome occurred in fewer participants in the liraglutide group than in
      the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% 
      confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven
      primarily by the new onset of persistent macroalbuminuria, which occurred in
      fewer participants in the liraglutide group than in the placebo group (161 vs.
      215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of
      renal adverse events were similar in the liraglutide group and the placebo group 
      (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute
      kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).
      CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual
      care, liraglutide resulted in lower rates of the development and progression of
      diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National
      Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
FAU - Mann, Johannes F E
AU  - Mann JFE
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Orsted, David D
AU  - Orsted DD
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Brown-Frandsen, Kirstine
AU  - Brown-Frandsen K
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Marso, Steven P
AU  - Marso SP
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Poulter, Neil R
AU  - Poulter NR
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Rasmussen, Soren
AU  - Rasmussen S
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Tornoe, Karen
AU  - Tornoe K
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Zinman, Bernard
AU  - Zinman B
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
FAU - Buse, John B
AU  - Buse JB
AD  - From KfH Kidney Center, Munich, and Friedrich Alexander University of Erlangen,
      Erlangen - both in Germany (J.F.E.M.); Novo Nordisk, Bagsvaerd, Denmark (D.D.O., 
      K.B.-F., S.R., K.T.); University of Texas Southwestern Medical Center, Dallas
      (S.P.M.); Imperial College London, London (N.R.P.); Lunenfeld-Tanenbaum Research 
      Institute, Mt. Sinai Hospital, University of Toronto, Toronto (B.Z.); and
      University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
CN  - LEADER Steering Committee and Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01179048
GR  - UL1 TR001111/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
CIN - N Engl J Med. 2017 Aug 31;377(9):885-887. PMID: 28854097
EDAT- 2017/08/31 06:00
MHDA- 2017/08/31 06:00
CRDT- 2017/08/31 06:00
AID - 10.1056/NEJMoa1616011 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.